The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

An innovative strategy for solid tumors involves using bispecific T-cell engagers to target the tumor stroma—the protective fibrotic tissue surrounding the tumor. This novel approach aims to first eliminate this physical barrier, making the cancer cells themselves more vulnerable to subsequent immune attack.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

To increase safety and efficacy, next-generation CAR-T therapies use "logic-gated" designs. These constructs only activate when they detect the co-expression of multiple antigens—a signature unique to tumor cells—thereby avoiding off-target toxicity on healthy tissues that may express only one of the antigens.

Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.

Cytospire targets well-validated antigens like EGFR, which were previously 'undruggable' by CD3 engagers due to severe toxicity on healthy cells. Their gamma delta T-cell platform solves this by enabling 'context-dependent killing,' discriminating between tumor and healthy tissue. This safety profile could unlock a portfolio of solid tumor targets previously considered too dangerous for this drug class.

Many promising solid tumor antigens (e.g., PSMA, HER2) are also on normal tissues, making them too toxic for T-cell engagers. By using masks that are cleaved only in the tumor microenvironment, these "dirty" targets become viable, dramatically expanding the therapeutic landscape for solid cancers.